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Introduction {#sec1}
============

Axon degeneration is a critical, early event in many neurodegenerative disorders. Studies of WLD^S^, an aberrant fusion protein with critical nicotinamide mononucleotide adenylyltransferase (NMNAT) activity responsible for the slow Wallerian degeneration phenotype, indicate this often shares molecular features with injury-induced axon degeneration ([@bib4]). New, endogenous regulators of Wallerian degeneration have emerged, so establishing interactions among them will be important for developing appropriate therapies ([@bib4; @bib15; @bib18]). While a conserved pathway is emerging, the relationship between NMNAT2 and sterile alpha and TIR motif containing 1 (SARM1), key regulators of axon degeneration with opposing influences, is still unknown ([@bib4]).

NMNAT2 is one of three naturally occurring mammalian NMNATs. Like WLD^S^, each robustly delays Wallerian degeneration when re-localized or sufficiently overexpressed ([@bib13; @bib14; @bib19; @bib22]), but only depletion of NMNAT2, not NMNAT1 or NMNAT3, triggers WLD^S^-sensitive neurite degeneration in neuronal cultures ([@bib9]). This suggests NMNAT2 is the isoform that contributes most to axon survival in a physiological context. *Drosophila* NMNAT ortholog, dNmnat, appears to have a similar role in flies ([@bib7]). Early loss of short-lived NMNAT2 in injured axons, prior to frank degeneration, has thus been proposed as a trigger for WLD^S^-sensitive axon degeneration and the point of WLD^S^ influence ([@bib4; @bib9]). This is supported by studies that show that a critical requirement for PHR1/Highwire ubiquitin ligase during Wallerian degeneration may be linked to its regulation of NMNAT2/dNmnat turnover ([@bib1; @bib21]) and the proposal that accumulation of the NMNAT substrate NMN, a predicted consequence of NMNAT2 loss, acts as a pro-degenerative signal ([@bib6]). Severe truncation of peripheral nerve axons and CNS axon tracts in NMNAT2-deficient embryos, likely responsible for their perinatal lethality, is also consistent with a critical axon survival function for NMNAT2 in vivo ([@bib10; @bib11]). Importantly, though, this developmental phenotype appears to be primarily due to an initial outgrowth defect rather than dying-back degeneration of established axons ([@bib10]).

SARM1, in contrast, has a pro-degenerative function. It is required for the normal, rapid progression of degeneration after injury and other WLD^S^-sensitive insults ([@bib8; @bib17]). Multimerization, mediated by its SAM (sterile α motif) domain, appears to be required for a pro-degenerative function dependent on its TIR (Toll-interleukin-1 receptor) domain ([@bib8]). Crucially, SARM1 depletion is currently the only known manipulation that delays WLD^S^-sensitive axon degeneration as robustly as expression of WLD^S^ or other NMNATs.

In this study, we used axon injury in nerves and neurons from *Sarm1*^−/−^ mice to establish the relationship between NMNAT2 loss and a SARM1-dependent function during WLD^S^-sensitive degeneration. Remarkably, we also find that mice lacking both NMNAT2 and SARM1 are viable, enabling us to examine the mechanistic origins of the developmental axon outgrowth defect associated with constitutive NMNAT2 deficiency.

Results {#sec2}
=======

SARM1 Promotes Axon Degeneration Downstream of NMNAT2 Loss {#sec2.1}
----------------------------------------------------------

NMNAT2 levels have previously been found to decline rapidly in the distal stumps of transected wild-type SCG and DRG neurites prior to their degeneration at ∼8 hr ([@bib9; @bib23]). Here, we find equivalent loss of NMNAT2 in wild-type and *Sarm1*^−/−^ SCG neurites by 4 hr after cut ([Figure 1](#fig1){ref-type="fig"}A), even though degeneration of transected *Sarm1*^−/−^ neurites is delayed for at least 3 days ([@bib17]). Levels of the NMNAT substrate, NMN, and product, NAD, have also been shown to respectively rise and fall in the distal stumps of transected wild-type sciatic nerves ([@bib6]) prior to axon degeneration, which occurs at around 36 hr ([@bib2]). This is consistent with a predicted loss of NMNAT2 in injured axons in vivo. Here, we find that these changes are not prevented in *Sarm1*^−/−^ nerves at 30 hr after lesion ([Figure 1](#fig1){ref-type="fig"}B), despite *Sarm1*^−/−^ axons being preserved for at least 14 days ([@bib17]). In fact, by 30 hr, NMN has risen significantly more than in wild-type nerves, and by 120 hr, NAD levels have dropped below those in wild-type nerves at 30 hr (a short time before they degenerate). Together, these data suggest SARM1 promotes Wallerian degeneration downstream or independently of NMNAT2 loss and consequent changes in NMN and NAD levels.

Although NMNAT2 loss has been strongly implicated as a trigger for Wallerian degeneration, this is difficult to prove definitively, as injury induces many simultaneous changes. We therefore assessed whether SARM1 is required during related, WLD^S^-sensitive axon degeneration induced specifically by small interfering RNA (siRNA)-mediated depletion of NMNAT2 ([@bib9]). We found distal neurites of *Sarm1*^−/−^ neurons are completely protected from *Nmnat2* siRNA-induced degeneration for at least 72 hr, and also from the later, slower loss of cell viability ([Figures 1](#fig1){ref-type="fig"}C and 1D). NMNAT2 depletion can thus trigger SARM1-dependent axon degeneration in the absence of injury or other initiating stimuli supporting a situation in which either SARM1 itself, or a SARM1-dependent activity of a convergent pathway, promotes WLD^S^-sensitive axon degeneration downstream of NMNAT2 loss.

SARM1 Promotes Axon Defects in Mice Lacking NMNAT2 {#sec2.2}
--------------------------------------------------

We next bred mice doubly homozygous for the *Nmnat2*^gtE^ gene trap allele (effectively a null allele; [@bib10]) and a *Sarm1* knockout allele ([@bib12]) to investigate whether SARM1 might also contribute to axon defects associated with constitutive NMNAT2 deficiency during development.

Intriguingly, whole-mount labeling of distal phrenic nerve branches in the diaphragm and of intercostal nerves in *Nmnat2*^gtE/gtE^;*Sarm1*^−/−^ embryos/newborn pups revealed clear and reproducible rescue of the peripheral nerve axon truncation defect associated with NMNAT2 deficiency in *Nmnat2*^gtE/gtE^ animals ([Figures 2](#fig2){ref-type="fig"}A and 2B). The underlying cause of this defect in *Nmnat2*^gtE/gtE^ embryos is restricted axon extension ([@bib10]); therefore, to obtain a quantitative measure of rescue by SARM1 deficiency, we compared neurite outgrowth in SCG explant cultures from *Nmnat2*^gtE/gtE^ and *Nmnat2*^gtE/gtE^;*Sarm1*^−/−^ embryos with that of relevant controls ([Figures 2](#fig2){ref-type="fig"}C and 2D). Strikingly, *Nmnat2*^gtE/gtE^;*Sarm1*^−/−^ neurite outgrowth matched that in *Sarm1*^−/−^ and *Nmnat2*^+/gtE^;*Sarm1*^−/−^ littermate cultures, as well as in wild-type and *Nmnat2*^+/gtE^ cultures assessed in parallel. Similar rescue was also seen in DRG cultures (not shown). The axon extension defect associated with a lack of NMNAT2 thus appears fully corrected in late-stage embryos and newborn mice deficient for SARM1. Consistent with this, while *Nmnat2*^gtE/gtE^ (and *Nmnat2*^gtE/gtE^;*Sarm1*^+/−^) pups die at birth, *Nmnat2*^gtE/gtE^;*Sarm1*^−/−^ mice in contrast are viable and reach weaning at the expected Mendelian ratios ([Figure 2](#fig2){ref-type="fig"}E). Adult *Nmnat2*^gtE/gtE^;*Sarm1*^−/−^ mice are also fertile and, despite subtle gender- and *Sarm1*-genotype-specific differences, their weights at 10 weeks are within a healthy range and similar to control groups ([Figure 2](#fig2){ref-type="fig"}F). Crucially, RT-PCR and immunoblotting confirmed that the *Nmnat2*^gtE^ allele remains effectively silenced on a *Sarm1*^−/−^ background ([Figures 2](#fig2){ref-type="fig"}G and 2H). This rules out reduced efficacy of the gene trap as being responsible for rescue of the phenotype.

As in injured nerves, SARM1 deficiency does not prevent expected changes to NMNAT metabolites in the brains of embryos lacking NMNAT2 ([Figure 3](#fig3){ref-type="fig"}A). In fact, the relative increase in NMN in *Nmnat2*^gtE/gtE^;*Sarm1*^−/−^ brains is greater than in *Nmnat2*^gtE/gtE^ brains, presumably due to rescued outgrowth of CNS axons, where changes, away from the influence of nuclear NMNAT1, should be greatest. A small, but significant, reduction in NAD is also evident in *Nmnat2*^gtE/gtE^;*Sarm1*^−/−^ brains. In contrast, heterozygosity for the *Nmnat2*^gtE^ allele does not significantly alter brain NMN or NAD levels on either *Sarm1* background. Interestingly, there is a trend toward higher NMN and NAD levels in *Sarm1*^−/−^ brains, independent of NMNAT2-related changes, and the total adenylate pool (ATP + ADP + AMP) is increased (1,764 ± 113 nmol/g tissue in *Sarm1*^−/−^ brains compared to 1,314 ± 97 in *Sarm1*^+/+^ brains; p = 0.009). Thus, SARM1 itself may have some influence over NAD and/or energy metabolism.

In case the complexity of whole brain concealed more marked changes specifically in axons, we also assessed nucleotide levels separately in DRG neurites and ganglia ([Figures 3](#fig3){ref-type="fig"}B and [S1](#app2){ref-type="sec"}). Indeed, consistent with NMNAT2 being the major axonal NMNAT, we detected a greater relative increase in NMN and decrease in NAD in *Nmnat2*^gtE/gtE^;*Sarm1*^−/−^ neurites than in brains. In contrast, changes in ganglia fractions were far more modest, indicating NMNAT2 has less influence in the cell body (and associated proximal neurite stumps). Surprisingly, accumulation of NMN was not evident in the limited neurite outgrowth in *Nmnat2*^gtE/gtE^ cultures. However, the NMN/NAD ratio is increased to the same extent as in *Nmnat2*^gtE/gtE^;*Sarm1*^−/−^ neurites, due to a much greater reduction in NAD, consistent with comparable loss of NMNAT activity. We speculate that, even though stunted *Nmnat2*^gtE/gtE^ neurites do not show signs of overt degeneration, their integrity could still be compromised, resulting in NMN and NAD efflux and the lower than expected levels of both nucleotides. Low NAD in *Nmnat2*^gtE/gtE^ ganglia fractions suggests this may also extend to proximal neurite stumps and possibly even cell bodies. Finally, as in brains, heterozygosity for the *Nmnat2*^gtE^ allele does not significantly alter NMN and NAD levels in either DRG fraction. This is consistent with overt normality of *Nmnat2*^+/gtE^ axons in both contexts.

Overall, these results indicate that SARM1 is critically involved in the manifestation of the phenotype of *Nmnat2*^gtE/gtE^ mice, with it, or a dependent activity, acting downstream of predominantly axonal alterations to NMN and NAD resulting from the lack of NMNAT2. Crucially, this suggests significant mechanistic overlap between WLD^S^-sensitive axon degeneration and the axon outgrowth defect in these mice.

NMN Contributes to the Limited Outgrowth of NMNAT2-Deficient Neurites {#sec2.3}
---------------------------------------------------------------------

We have previously implicated rising NMN, rather than declining NAD, as a critical pro-degenerative event in injured axons, in part by showing that blocking NMN synthesis with NAMPT inhibitor FK866 and scavenging NMN via ectopic expression of bacterial NMN deamidase (converting it to NaMN) both delay Wallerian degeneration ([@bib6]). We therefore used these reagents to investigate whether NMN also limits outgrowth and survival of axons lacking NMNAT2.

First, we tested the prediction that survival of *Nmnat2*^gtE/gtE^;*Sarm1*^−/−^ SCG neurites should be impaired by ectopic re-expression of SARM1 due to re-activation of a SARM1-dependent degeneration pathway downstream of NMNAT2 deficiency, and assessed whether these events are NMN-dependent using co-expression of NMN deamidase ([Figures 4](#fig4){ref-type="fig"}A and 4B). While ectopic re-expression of SARM1 (C-terminal GFP tagged) in *Sarm1*^−/−^ neurons (with normal NMNAT2) unexpectedly induced some neurite degeneration by 24 hr, it induced much more extensive degeneration of *Nmnat2*^gtE/gtE^;*Sarm1*^−/−^ neurites (lacking NMNAT2) and, crucially, this was significantly reduced by co-expression of NMN deamidase (N-terminal GFP tagged). This suggests that, as well as promoting Wallerian degeneration, NMN also drives SARM1-dependent degeneration in this context. Importantly, these experiments additionally confirm that rescue of *Nmnat2*^gtE/gtE^;*Sarm1*^−/−^ axons is due to SARM1 deficiency and not other, undefined changes resulting from mouse breeding.

Next, we used FK866 to assess whether NMN accumulation also limits *Nmnat2*^gtE/gtE^ neurite outgrowth ([Figures 4](#fig4){ref-type="fig"}C and 4D). Interestingly, FK866 stimulated additional outgrowth of *Nmnat2*^gtE/gtE^ DRG neurites, but only for about 24 hr, after which neurites underwent complete degeneration. Because FK866 causes simultaneous reductions to both NMN and NAD in neuronal cultures ([@bib6]), we considered that this later degeneration could be due to an extreme reduction in NAD in neurites now lacking both NAMPT and NMNAT2 activities and/or secondary to neuronal death caused by reduced somal NAD. To overcome this, we co-treated cultures with potential sources of NAD. NAD itself was ineffective ([Figure S2](#app2){ref-type="sec"}), likely due to inefficient entry into neurons and/or failed conversion of more readily internalized NAD precursors (generated by extracellular degradation) back into NAD when NMNAT2 is absent ([@bib6; @bib16]), possibly even leading to further NMN accumulation in *Nmnat2*^gtE/gtE^ neurites. However, NaAD, an alternative source of NAD via endogenous NAD synthetase ([@bib6]), did promote additional outgrowth and survival of *Nmnat2*^gtE/gtE^ neurites when added with FK866 (but, importantly, not when added alone). Together, these data suggest increased NMN does contribute to the restricted outgrowth of *Nmnat2*^gtE/gtE^ neurites, although rescue of *Nmnat2*^gtE/gtE^ neurite outgrowth by FK866 and NaAD still falls some way short of the outgrowth of wild-type neurites treated in the same way (despite this also being slightly inhibitory) ([Figure 4](#fig4){ref-type="fig"}C). Therefore, either inhibition of NAMPT by FK866 or clearance of pre-accumulated NMN is relatively ineffective and/or outgrowth is not exclusively limited by NMN-dependent events.

Discussion {#sec3}
==========

Despite their shared ability to profoundly influence axon survival after injury, no link between NAD metabolism and SARM1 function had previously been firmly established. Our studies show not only that either SARM1 itself, or a SARM1-dependent convergent activity, acts downstream of NMNAT2 loss and resulting changes to key NMNAT metabolites to promote WLD^S^-sensitive axon degeneration but also that this also occurs downstream of NMNAT2 deficiency and dependent changes during development to impair axon outgrowth and limit mouse survival. Intriguingly, an NMNAT2 depletion-dependent accumulation of NMNAT substrate, NMN, also appears to be a critical pro-degenerative signal in both situations (this study; [@bib6]), strongly suggesting they are each mediated by activation of the same NMN- and SARM1-dependent degeneration pathway. Importantly, our data appear to rule out any lasting stabilization of NAD or reduced accumulation of NMN as part of the mechanism underlying protection of SARM1-deficient axons, although intriguing increases in total adenylate pool and steady-state levels of NMN and NAD in *Sarm1*^−/−^ brains may yet be found to be involved.

Overall, our studies suggest either that changes resulting from NMNAT2 loss directly activate a pro-degenerative SARM1 function in axons in a linear pathway or that parallel SARM1-dependent and NMNAT2 loss-dependent signals merge at a common downstream step in a convergent pathway ([Figure S3](#app2){ref-type="sec"}). Importantly, the critical SARM1-dependent event in either model likely acts upstream of calpain activation ([@bib23]). Given that NMNAT2 depletion alone can activate SARM1-dependent neurite degeneration, the convergent pathway model would appear to require that SARM1 has constitutive pro-degenerative activity, with activation or disinhibition of a critical downstream step only occurring after NMNAT2 loss. While a proposed regulatory role for the N-terminal domain of SARM1 ([@bib8]) appears more consistent with activation of a pro-degenerative function in a linear pathway, our finding that exogenous expression of SARM1(-GFP) induces some degeneration even when NMNAT2 is present (in *Sarm1*^−/−^ neurons) suggests it could have some constitutive pro-degenerative activity (although conditions in these assays could also influence this outcome). Understanding precisely how endogenous SARM1 functions in the context of NMNAT2 loss and NMN accumulation during axon degeneration, and how this relates to other cellular roles of SARM1 ([@bib4]), will therefore be an important goal for future studies.

We had previously proposed that the early, limited extension of axons lacking NMNAT2 reflects restricted supply of an NMNAT-activity-dependent molecule required for axon growth, with NAD being a prime candidate ([@bib10]). However, initially improved outgrowth of *Nmnat2*^gtE/gtE^ neurites further deprived of NAD by FK866 challenges this idea, and the involvement of SARM1 instead suggests these neurites stop extending at the point where SARM1-dependent degeneration becomes active. In light of our findings, we speculate that NMN concentration may determine this activity. We predict that, due to a diminishing influence of nuclear NMNAT1, NMN in NMNAT2-deficient axons will rise as a function of distance from the soma, with some axon outgrowth possible up to the point at which a critical threshold is exceeded and SARM1-dependent degeneration is triggered.

NAD plays a key role in many diverse cellular functions ([@bib5]), so the fact that significant reductions in NAD do not prevent the delayed degeneration of cut SARM1-deficient axons or limit the normal growth and survival of intact axons lacking both NMNAT2 and SARM1 (in culture and in mice) was somewhat surprising. This, together with the ability of FK866 to delay degeneration of cut axons ([@bib6]) and temporarily rescue *Nmnat2*^gtE/gtE^ neurite outgrowth, despite further depletion of NAD, clearly indicates that fairly substantial reductions in NAD are not necessarily detrimental. However, it would be surprising if greater NAD depletion did not limit axon survival in some situations.

On its own, survival of *Nmnat2*^gtE/gtE^;*Sarm1*^−/−^ mice for several months with no overt problems suggests very strong correction of the defects associated with constitutive NMNAT2 deficiency during early development. However, it will still be critical to establish the precise extent and duration of this rescue in an aging study. Nevertheless, these mice already represent a unique resource for the identification or confirmation of other early pro-degenerative events triggered by NMNAT2 loss and NMN accumulation, given that our data suggest an activated degeneration pathway is paused at a SARM1-dependent step in *Nmnat2*^gtE/gtE^;*Sarm1*^−/−^ axons. For example, SARM1 appears to act downstream of reactive oxygen species accumulation, ATP depletion, and Ca^2+^ influx when cell death and axon degeneration are induced by the mitochondrial toxin carbonyl cyanide *m*-chlorophenyl hydrazone (CCCP) ([@bib20]), but it will be important to establish whether these changes also occur downstream of NMNAT2 loss during WLD^S^-sensitive degeneration. They should also be particularly useful for studying non-axonal phenotypes associated with NMNAT2 deficiency that may be SARM1 independent, such as its role in cardiac hypertrophy ([@bib3]).

To conclude, these studies have now firmly established the order of two core events in an emerging WLD^S^-sensitive and SARM1-dependent axon degeneration pathway. As additional steps are added, it will become increasingly apparent how this relates to other cell-death programs and how it might be most effectively targeted in axonal disorders. Crucially, the lack of any overt defects in adult *Nmnat2*^gtE/gtE^;*Sarm1*^−/−^ mice suggest that if effective targeting of this pathway can be achieved, it could potentially provide long-term relief from symptoms without major side effects.

Experimental Procedures {#sec4}
=======================

Animals, Genotyping, and Primary Neuronal Cultures {#sec4.1}
--------------------------------------------------

Animal work was carried out in accordance with the Animals (Scientific Procedures) Act, 1986, under Project License PPL 70/7620. Primers used for PCR genotyping of mice are listed in the [Supplemental Experimental Procedures](#app2){ref-type="sec"}.

Explant cultures of superior cervical ganglia (SCGs) from embryonic day 18.5 (E18.5) mouse embryos and postnatal day 0 (P0) to P2 pups and dorsal root ganglia (DRGs) from E13.5/14.5 and E17.5/E18.5 embryos and P0 pups, and dissociated SCG neuron cultures (P0--P2), were set up as described previously ([@bib10; @bib9]).

Neurite Outgrowth Assays {#sec4.2}
------------------------

Neurite outgrowth assays were performed and quantified as described previously ([@bib10]). NAMPT inhibitor FK866 (100 nM, generously supplied by the National Institute of Mental Health), NaAD (250 μM, Sigma-Aldrich), NAD (1 mM, Sigma-Aldrich), or NMN (1 mM, Sigma-Aldrich) were added to E17.5/E18.5 *Nmnat2*^gtE/gtE^ DRG explant cultures at 2 days in vitro as described.

RT-PCR Analysis and Immunoblotting {#sec4.3}
----------------------------------

Whole brains from E18.5 mouse embryos and neurite fractions from SCG explant cultures were processed as described previously for the generation of RNA and/or protein extracts ([@bib10; @bib9]). Primers for RT-PCR, and primary antibodies and concentrations for immunoblotting, are listed in the [Supplemental Experimental Procedures](#app2){ref-type="sec"}.

Determination of NMN and NAD Levels {#sec4.4}
-----------------------------------

NMN and NAD measurements in whole brains from E18.5 embryos or newborn (P0) pups, uncut or lesioned sciatic nerves from adult mice, and neurite and ganglia fractions from DRG cultures (prepared as for SCG cultures in [@bib9]) were performed using UV-C18 high-performance liquid chromatography (HPLC) and/or spectrofluorometric HPLC analysis essentially as described previously ([@bib6]).

Microinjections, Labeling/Immunostaining, and Microscopy {#sec4.5}
--------------------------------------------------------

Injections and quantification of neurite/cell-body survival were performed essentially as described previously ([@bib9]). Plasmids and siRNAs injected are listed in the figure legends and in the [Supplemental Experimental Procedures](#app2){ref-type="sec"}.

Anterograde labeling of intercostal nerve axons with the lipophilic dye DiI (1,1′-dioctadecyl-3,3,3′,3′-tetramethylindocarbocyanine perchlorate) in fixed P0 mouse pups and whole-mount neurofilament light-chain immunostaining of fixed diaphragms from E17.5/E18.5 embryos were performed as described previously ([@bib10]).

Phase-contrast and fluorescence images of primary cultures and stained/labeled tissues were acquired as described previously ([@bib10]). Image processing is described in the [Supplemental Experimental Procedures](#app2){ref-type="sec"}.

Statistical Analysis {#sec4.6}
--------------------

Appropriate statistical tests were performed using Prism software (GraphPad Software). The Student's t test, ANOVA with Tukey's or Dunnett's post hoc correction (as applicable), and Pearson's chi-square test were used in this study. A p value \> 0.05 was considered not significant, and ^∗^ indicates p \< 0.05, ^∗∗^ indicates p \< 0.01, and ^∗∗∗^ indicates p \< 0.001.
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![SARM1 Acts Downstream of NMNAT2 Loss during Axon Degeneration\
(A) Representative immunoblot of uncut (0 hr) and 4-hr-cut wild-type and *Sarm1*^−/−^ SCG neurite extracts probed for NMNAT2 and β-actin (sample control). NMNAT2 migrates at ∼32 kDa. Quantification of normalized NMNAT2 levels (to β-actin), is shown below with 4-hr data presented relative to uncut (set at 1). Means ± SEM are plotted (n = 3; p = 0.86 wild-type versus *Sarm1*^−/−^ at 4 hr).\
(B) NMN and NAD levels in uncut, and 30-hr- or 120-hr-lesioned wild-type and *Sarm1*^−/−^ sciatic nerves. Means ± SEM are plotted (n = 3--5). Levels in 120-hr-cut wild-type nerves were not determined (ND) as their axons are degenerated.\
(C) Representative images of distal neurites of wild-type and *Sarm1*^−/−^ SCG neurons 24 and 72 hr after injection with 100 ng/μl *Nmnat2* siRNA (si*Nmnat2*) and 10 ng/μl pEGFP-C1 (expressed EGFP allows visualization of the neurites of injected neurons).\
(D) Quantification of survival of wild-type (WT) and *Sarm1*^−/−^ SCG neurites (left) and cell bodies (right) for 3 days after injection with pEGFP-C1 and si*Nmnat2* or non-targeting siRNA (si*NT*) as in (C). Means ± SEM are plotted (n = 3--4).](gr1){#fig1}

![Normal Development and Survival of *Nmnat2*^gtE/gtE^;*Sarm1*^−/−^ Mice\
(A) Neurofilament-L immunostaining of diaphragms from E18.5 *Nmnat2*^gtE/gtE^ and *Nmnat2*^gtE/gtE^;*Sarm1*^−/−^ embryos (montages representative of n = 3 for each genotype). Boxed areas are magnified (right). Distal branches of phrenic nerves were present in wild-type, *Nmnat2*^+/gtE^, *Sarm1*^−/−^, and *Nmnat2*^+/gtE^;*Sarm1*^−/−^ embryos as expected (not shown).\
(B) DiI-labeled intercostal nerves in ribcages from P0 *Nmnat2*^gtE/gtE^ and *Nmnat2*^gtE/gtE^;*Sarm1*^−/−^ pups (montages, representative of n = 3 for each genotype). Nerve truncation was seen in all *Nmnat2*^gtE/gtE^ pups but was rescued in all *Nmnat2*^gtE/gtE^;*Sarm1*^−/−^ pups.\
(C) Quantification of radial neurite outgrowth over 7 days for E18.5 SCG explant cultures of the genotypes listed. Means ± SEM are plotted (n = 3--6 embryos of each genotype, average of both ganglia). Extension of the majority of *Nmnat2*^gtE/gtE^ neurites (mass) and a more robust sub-population (max) are both shown.\
(D) Representative images of *Nmnat2*^gtE/gtE^ and *Nmnat2*^gtE/gtE^;*Sarm1*^−/−^ neurite outgrowth at 7 days in vitro in E18.5 SCG explant cultures. Mass and max extension of *Nmnat2*^gtE/gtE^ neurites are marked (continuous and dashed lines).\
(E) Viability of offspring from *Nmnat2*^+/gtE^ or *Nmnat2*^+/gtE^;*Sarm1*^−/−^ crosses.\
(F) Weights of 10-week-old male or female *Nmnat2*^gtE/gtE^;*Sarm1*^−/−^ mice relative to indicated control groups. Both individual weights and means ± SEM are plotted. The weights of different genotypes in control groups do not vary significantly.\
(G) Representative RT-PCR analysis of *Nmnat2*, *Sarm1*, and *Actb* (sample control) mRNA levels in E18.5 embryo brains of the indicated genotypes. Quantification of normalized *Nmnat2* levels (to *Actb*), relative to wild-type levels, is shown below. Means ± SEM are plotted (n = 3).\
(H) Representative immunoblots (of n = 3) showing NMNAT2, SARM1, and ßIII-tubulin (sample control) expression in brains from E18.5 embryo of the indicated genotypes.](gr2){#fig2}

![NMN and NAD Changes Resulting from a Lack of NMNAT2 during Development Occur in the Absence of SARM1\
(A) NMN and NAD levels (nmol/g tissue) and NMN/NAD ratios in brains from E18.5 embryos/P0 pups of the indicated genotypes. Means ± SEM are plotted (n = 5--7 each genotype). Data for samples wild-type for *Sarm1* (red tones) have been presented previously in a different format ([@bib6]). Re-use of the same dataset here allows direct comparison with the *Sarm1*^−/−^ background data (blue tones), which was obtained in parallel.\
(B) NMN and NAD levels (nmol/mg extracted protein) and NMN/NAD ratios in separate neurite or ganglia fractions from 7-days-in-vitro explant cultures of DRGs from E13.5/14.5 embryos of the indicated genotypes. Ganglia fractions contain short proximal neurite stumps as well as cell bodies. Means ± SEM are plotted (n = 3--5 each genotype). See also [Figure S1](#app2){ref-type="sec"}, where data in (B) are presented as relative changes.](gr3){#fig3}

![Pharmacological and Genetic Inhibition of NMN Accumulation Promotes Growth and Survival of NMNAT2-Deficient Neurites\
(A) Representative images of neurites of *Sarm1*^−/−^ or *Nmnat2*^gtE/gtE^;*Sarm1*^−/−^ SCG neurons 24 hr after injection with 6.25 μg/μl Texas red dextran (for rapidly labeling neurites of injected neurons) together with 40 ng/μl GFP-NMN deamidase expression construct and 10 ng/μl pEGFP-C1 (GFP-NMNd (& GFP)), 10 ng/μl SARM1-GFP expression construct and 40 ng/μl pEGFP-C1 (SARM1-GFP (& GFP)), or 10 ng/μl SARM1-GFP and 40 ng/μl NMN deamidase-GFP expression constructs (SARM1-GFP & GFP-NMNd). SARM1-GFP induces degeneration of the proximal ∼1--2 mm of neurites, presumably shortly after exiting the soma.\
(B) Quantification of neurite survival in experiments described in (A). Means ± SEM are plotted (n = 3--7 each treatment). Neurite survival after GFP-NMNd (& GFP) expression is not significantly different from GFP alone (not shown).\
(C) Quantification of neurite outgrowth over 7 days for explant cultures of DRGs taken from E18.5 *Nmnat2*^gtE/gtE^ embryos (left) or wild-type embryos (right) treated with FK866 and/or NaAD after 2 days in vitro. Means ± SEM are plotted (n = 3--6 each treatment, statistical significance shown relative to untreated).\
(D) Representative phase contrast images showing the physical appearance of treated *Nmnat2*^gtE/gtE^ DRG neurites (if present) at 5 days in vitro (3 days after compound addition). See also [Figures S2](#app2){ref-type="sec"} and [S3](#app2){ref-type="sec"}.](gr4){#fig4}
